1996
DOI: 10.1016/s0092-8674(00)80125-7
|View full text |Cite
|
Sign up to set email alerts
|

A Signaling Pathway to Translational Control

Abstract: facility for mRNAs. Rapamycin treatment inhibits each of these growth factor-stimulated effects (Jefferies et Howard Hughes Medical Institute al., 1994; Terada et al., 1994; Nielsen et al., 1995). Since Department of Chemistry and Chemical Biology the change in association of these mRNAs with polyribo-and Program in Immunology somes indicates that these transcripts are regulated at Harvard University the initiation phase, the signaling pathway inhibited by 12 Oxford St.rapamycin appears to regulate early ste… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

10
233
3
2

Year Published

1998
1998
2019
2019

Publication Types

Select...
10

Relationship

0
10

Authors

Journals

citations
Cited by 356 publications
(248 citation statements)
references
References 19 publications
10
233
3
2
Order By: Relevance
“…Unphosphorylated 4E-BP1 binds to RNA cap-binding protein eIF-4E, inhibiting its coupling to mRNA and the translational initiation complex required for initiating translation of cap-dependent mRNAs, a subset of mRNAs with regulatory elements located in the 5'-untranslated regions (UTRs). 16 Activated mTOR, leads to phosphorylation of 4E-BP1, release of eIF-4E to bind to cap mRNA transcripts and other initiation complex proteins, and the initiation of cap-dependent translation. 4 This interaction results in an increase in translation rates cap-dependent mRNAs, including several proteins controlling cell proliferation.…”
Section: Biochemistry Of Pi3k-akt-mtor Pathwaymentioning
confidence: 99%
“…Unphosphorylated 4E-BP1 binds to RNA cap-binding protein eIF-4E, inhibiting its coupling to mRNA and the translational initiation complex required for initiating translation of cap-dependent mRNAs, a subset of mRNAs with regulatory elements located in the 5'-untranslated regions (UTRs). 16 Activated mTOR, leads to phosphorylation of 4E-BP1, release of eIF-4E to bind to cap mRNA transcripts and other initiation complex proteins, and the initiation of cap-dependent translation. 4 This interaction results in an increase in translation rates cap-dependent mRNAs, including several proteins controlling cell proliferation.…”
Section: Biochemistry Of Pi3k-akt-mtor Pathwaymentioning
confidence: 99%
“…Angiotensin II increases the release of norepinephrine in presynaptic junctions, increases the pressure response to norepinephrine and increases the sympathetic tonus. 37 One of the hypotheses for the result found was that in such subjects the trigger for the development of LVH would be a RAS hyperactivity, or its predominance over the SNS. This initial hypothesis we present seems to be in accordance with what Polonia et al 8 assumed when, following catecolamine dosage in subjects with such characteristics, they suggested the hypothesis of sympathetic hyperactivity for such phenomenon.…”
Section: Differences In Lvmimentioning
confidence: 99%
“…This protein consists of a 460 kDa catalytic subunit whose kinase activity is enhanced by ends of DNA molecules in the presence of the co-factors Ku70 and 86 (Jackson and Jeggo, 1995). In addition, the PIK family includes the TOR proteins, which are targets of the FKBP-rapamycin complex (Brown and Schreiber, 1996;Hall, 1996), and the ataxia telangiectasia gene product, ATM (Savitsky et al, 1995). A subset of the PIK family contains an additional region of homology termed the rad3 homologous region, and this subfamily includes the S. cerevisiae MEC1 and TEL1 (Greenwell et al, 1995;Morrow et al, 1995) and the Drosophila mei-41 gene product (Hari et al, 1995).…”
Section: Introductionmentioning
confidence: 99%